Introduction
Multifunctional CaMKs (CaMKI, CaMKII and CaMKIV) are important mediators of intracellular Ca 2+ signalling that play pleiotropic roles in cell physiology. These serine-threonine (Ser/Thr) protein kinases are activated upon Ca 2+ /CaM binding. The upstream CaMK kinases (CaMKKs) phosphorylate a critical Thr 200 in the activation-loop to activate CaMKIV, whereas CaMKII is fully activated by autophosphorylation of its own Thr 286 [1, 2] . Ca (cAMP) response element binding protein (CREB), activating transcription factor (ATF), serum response factor (SRF), and transcriptional co-factors including CREB binding protein (CBP) [10] . Embryonic expression of CaMKIV correlates with periods of differentiation and terminal mitoses, supporting for this kinase a pivotal role in regulation of cell differentiation [11] . Indeed, in hematopoietic stem cells (HSCs), CaMKIV/CREB/CBP pathway restricts cell proliferation by expression of Bcl-2, a pro-survival protein with additional roles in cell quiescence [12] . In cancer cells, CaMKs appear to play a role in aggressiveness: CaMKK2 signaling through adenosine monophosphate dependent protein kinase (AMPK) [13] and/or CaMKI [3] modulates cell migration, invasiveness and malignancy in prostate cancer and medulloblastoma [14, 15] . Notably, CaMKIV is not expressed in these two cancer cell types, a feature that the authors attributed to reduced expression of genes required for differentiation [14] .
The ubiquitously expressed, multimeric CaMKII is predominantly cytoplasmic, although 3 alternatively spliced variants: α B ,γ A , and δ B are targeted to the nucleus [16, 17] . CaMKII exerts a broad range of biological functions, and is an important regulator of cell proliferation [18, 19] . It modulates Raf1 activity leading to extra-cellular receptor kinase (ERK) activation and induction of cell proliferation. The interplay between CaMKII and ERK has been observed in several cell types including thyroid [20, 21] , fibroblasts [22] , skeletal muscle [23] and vascular smooth muscle [24] , suggesting that it is a general mechanism in the control of cell proliferation. CaMKII is also a target of RET-PTC oncogene, raising the possibility that it plays a central role in the abnormal growth of tumor cells [25] .
Many studies suggest the involvement of CaMKII in the homeostasis of tumor cells. Indeed, Si and Collins reported that myeloid leukemia cell lines as well as primary acute myeloid leukemia (AML) patient samples express elevated levels of activated CaMKII. CaMKII promotes G 1 /S cell cycle progression [26] and its inhibition impairs myeloid leukemia cell proliferation. Leukemia cells undergoing growth arrest and/or terminal differentiation present markedly reduced levels of CaMKII [26] , suggesting that downregulation of CaMKII may be a pre-requisite for inducing terminal differentiation in myeloid leukemia cells.
Because of the reciprocal aspects of CaMKII and CaMKIV on proliferation [12] and terminal differentiation [11, 27, 28] in hematopoietic progenitors, we hypothesized that CaMKIV may be repressed in a CaMKII dependent manner in myeloid leukemia cells. In the present study, we investigated a potential cross-talk between CaMKII and CaMKIV in human myeloid leukemia U937 cells [29] , which express very low CaMKIV and high CaMKII levels. We found that CaMKII represses CaMK4 transcription and promotes proliferation in human myeloid leukemia cells. On the other hand, transgenic enhanced expression of CaMKIV negatively modulates CaMKII activity and induces G 0 /G 1 cell cycle arrest in these malignant cells. We propose that CaMKII and CaMKIV counterregulation is not restricted to leukemia cells and can be exploited in the development of targeted therapies against myeloid leukemia and other myeloid disorders.
Materials and methods

Cell culture and reagents
U937 and K562 (CRL1593.2 and CCl243, respectively, American Type Culture Collection (ATCC), Manassas, VA) were cultured in RPMI-1640 Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Invitrogen). Human embryonic kidney HEK 293A cells (R70507, Invitrogen) were grown in DMEM supplemented with 10% FBS (Invitrogen). Cells were stimulated with 2 μM ionomycin (Sigma, St. Louis, MO) for 15 min or with 10% FBS following 12 h serum starvation. CaMKII pharmacological inhibition was obtained with 10 μM of the CaMKs inhibitor KN93 (Biomol Plymouth Meeting, PA); or with 5 μM of the CaMKII selective inhibitory peptide, AntCaNtide [30] .
RNA interference
Four CaMKIIγ-specific shRNA (SureSilencing shRNA plasmids) and control shRNA vector were purchased from SuperArray. The targeted sequences are shRNA1: ACCTGCTGCTGGCGAGTAAAT; shRNA2;GAACGTGA GGCTCGGATATGT; shRNA3: GAGGCCTACACGAAGATTTGT; shRNA-4: GAGTGTTTGCGCAAGTTCAAT. CaMKIIγ-shRNA design was based on the GenBank accession number NM_001222. CaMKIIγ-shRNA transfections were performed using Attractene Transfection Reagent.
These four plasmids were, first, transiently transfected in U937 cells according to the manufacturer's instructions, and then selected in G418 (800 μg/mL) for 10 d. We first indentified one shRNA that caused N 80% reduction in the endogenous CaMKIIγ levels.
Lentiviral infection
Lentivirus-green fluorescent protein (GFP) constructs were generated and characterized as mentioned before [31] . Briefly, full-length WT CaMKIVcDNA (a gift from Dr. Anthony R. Means, Duke University Medical Center) was cloned into a Lenti-green fluorescent protein (GFP) vector [32] . Empty Lenti-GFP-control ("Mock"), Lenti-GFP-CaMKIV ("CaMKIV") and Lenti-GFP-CaMKIV-K71M viruses were generated as previously described [3, 4] using second generation helper plasmids in 293T cells (a gift from Dr. Anthony R. Means, Duke University Medical Center and described in Kitsos et al. [12] ). Virus titers were calculated using 293T cells and CaMKIV expression confirmed by immunoblotting. Approximately 2 × 10 6 of U937 cells were infected with control (Mock)
or Lenti-GFP-CaMKIV (CaMKIV) viruses at a multiplicity of infection of 10:1.
Cell viability and [
H] thymidine (T) incorporation assays
50,000 cells/well were counted daily following trypan blue staining (Invitrogen). 5000 cells were serum-starved for 12 h, and DMEM-10% FBS with 0.5 μCi [ 
Cell cycle distribution assay
Cells were fixed in 70% ethanol, incubated with 0.02 mg/ml propidium iodide (PI) and 0.25 mg/ml ribonuclease A (Sigma), and analyzed for DNA content (FACScan, BD). Acquisition and analyses were performed using CellQuest (BD) software.
Annexin V apoptosis assay
× 10
6 cells were incubated with AnnexinV-PE and PI (BDPharmingen, USA) and analyzed by flow cytometry. Samples were acquired with a CYAN flow cytometer (DAKO Corporation, San Jose, CA) and analyzed using SUMMIT® software.
Ki-67 staining
Cells were incubated with Ki-67-PE antibody and 7-amino actinomycin D (7AAD, BD) and analyzed (FACSAria, BD).
Bromo deoxy uridine (BrdU) labeling
Cells were pulse-labeled with 10 μM BrdU (Sigma). Samples were processed and incubated with BrdU-PE antibody and 7AAD (BD), and analyzed on a FACSAria.
Transient transfection and dual luciferase assay
HEK 293A cells were transiently transfected with 0.1 μg of renilla luciferase pRLTK vector and 1 μg each of fire fly luciferase reporter construct containing a CaMK4 promoter harboring RARβ response elements (RRE) [33] , expression constructs encoding RAR-β, chicken ovalbumin upstream promoter transcription factor (COUP-TF) and CaMKII. Two days later, transfected cells were treated with 2 μM retinoic acid (Sigma) for 2 h and assayed using a dual Luciferase Assay Reporter System Kit (Promega Co., Madison, WI).
CaMKII activity assays
Endogenous CaMKII was immunoprecipitated with 5 μL of antiCaMKII antibody and 25 μL of protein G plus/protein A agarose beads/ 1 mg total cell extract (Santa Cruz, CA). CaMKII was incubated for 30 min at 30°C with 1 mM CaCl2 and 1 μM CaM in 50 μl of reaction mixture (50 mM HEPES pH 7.5, 10 mM MgCl2, 0.5 mM dithiothreitol (DTT), 100 nM microcystin, 0.1 mM cold ATP). In a second reaction step, an aliquot from the first reaction was incubated with the CaMKII substrate Autocamtide and [32P]-γATP (GE-Amersham, Piscataway, NJ); EGTA was added to quantify CaMKII autonomous activity.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted with a RNA 4-PCR kit (Applied Biosystems, Foster City, CA) and reverse transcribed using a High Capacity Reverse Transcriptase Kit (Applied Biosystems). QRT-PCR was performed by Bio-Rad IC5 thermo-cycler (Bio-Rad Laboratories, Hercules, CA). Primers sequences used for hCaMKIV are: 5′-GGC ACA GGC TGA GCT GAT G-3′ forward and 5′-CTA GTT CCA GGT CAG CCA CCT TT-3′ reverse primers. Cycle threshold (Ct) values from 3 independent experiments were normalized to the internal β-actin control. The ratio of fold change was calculated using the Pfaffl method [34] .
Patient specimen collection
AML specimens were obtained from peripheral blood or bone marrow of patients following informed consent at the time of diagnostic biopsy. Weekly calibration using beads (Beckman Coulter Inc. Brea, CA) was performed. Whole BM samples in EDTA were washed 3 times in phosphate-buffered saline (PBS) and resuspended with 1% bovine serum albumin in PBS. 100 μL were incubated with each of the following titered monoclonal antibodies (MoAbs) for 15 min: 5 μL HLA-DR FITC, 5 μL Myeloperoxidase FITC, 5 μL CD2-PeCy7, 5 μL CD3 PE, 5 μL CD4 PE, 5 μL CD5-PeCy7, 5 μL CD8-PeCy5, 5 μL CD7 FITC, 5 μL CD10 PE, 5 μL CD11a FITC, 5 μL CD11b-PeCy5, 5 μL CD11c PE, 5 μL CD13-PeCy5, 5 μL CD14 FITC, 5 μL CD15 FITC, 5 μL CD19 PeCy5, 5 μL CD20 PE, 5 μL CD24 PE, 5 μL CD25 FITC, 5 μL CD33 PeCy5, 5 μL CD34 PeCy7, 5 μL CD45RO PE, 5 μL CD45RA PE (Beckman Coulter Inc. Brea, CA). Erythrocytes were lysed by BD FACS lysing solution. Cells were pelleted (416 g for 5 min), washed and resuspended in 0.5 mL of 1% of paraformaldehyde. 160,000 to 1,000,000 total BM cells were acquired/sample. Small samples of normal bone marrow were collected from the sack left following transplant.
Flow cytometry on primary human cells
Bone marrow aspirate specimens were tested on a dual laser system Beckman Coulter, Cytomics FC500 (Beckman Coulter Inc. Brea, CA) using CXP software (see SM).
Statistical analysis
Student's t-test was used for statistical significance; a p-value b 0.05 was deemed significant.
Results
Inhibition of CaMKII activity elevates CaMKIV expression
Pharmacological inhibition of CaMKII activity induces cell cycle arrest in several cell types including myeloid leukemia cells [5, 7, 26] . To identify the underlying mechanism of growth inhibition, U937 cells were treated with 10 μM KN93. Whereas the levels of total CaMKII did not change, autophosphorylation of CaMKII became significantly reduced within 6 h of KN93 treatment, and completely repressed after 24 h (p-CaMKII, Fig. 1A ). In contrast to CaMKII, which is abundantly expressed in U937 myeloid leukemia cells, expression of CaMKIV is very low ( Fig. 1A and Supplementary Fig. S1 ). However, levels of CaMKIV increased as a function of time in U937 cells following exposure to KN93 (Fig. 1A ). This result was reproduced also in K562 cells, confirming that this mechanism is not restricted to U937 cells (Fig. 1F ). To understand whether CaMKIV increase occurs at the transcriptional level, we analyzed CaMK4 mRNA in U937 cells treated with KN93. As indicated in Fig. 1B , CaMK4 mRNA levels increase by 24 h and become maximally up-regulated by 72 h after KN93 treatment, indicating that CaMKIV increase following CaMKII inhibition involves enhanced Camk4 transcription. To further confirm the effect of CaMKII inhibition on CaMKIV expression, we analyzed CaMK4 mRNA and protein levels in U937 cells following treatment with the CaMKII-specific inhibitory peptide, AntCaNtide [21] [22] [23] 30] . Accordingly, antCaNtide treatment resulted in a time-dependent increase of CaMKIV protein levels (Fig. 1C) . Inhibition of CaMKII activity using AntCaNtide also resulted in a significant induction of CaMK4 mRNA within 6 h (Fig. 1D) . Altogether, these data suggest that inhibition of CaMKII promotes CaMK4 mRNA synthesis. Since CaMKIIγ is the predominantly expressed isoform of CaMKII in both myeloid cells and U937 [35, 36] , we also determined the effect of silencing CaMKIIγ by shRNA on CaMKIV expression in this latter cell line. As shown in Fig. 1E , CaMKIIγ shRNA in U937 cells increased CaMKIV protein expression in a similar way of KN-93 and AntCaNtide treatments. This result is consistent with CaMKIV upregulation after pharmacological inhibition of CaMKII.
It is known that CaMKII directly binds to and phosphorylates the nuclear hormone receptor transcription factor RAR [35] . In myeloid cells, this phosphorylation results in enhanced binding of RAR to transcriptional co-repressors, inhibiting RAR-mediated transcription from target genes. The 5′ flanking region of human CaMK4 promoter contains RAR response elements (RRE) and treatment with retinoic acid (RA) results in transactivation of the CaMK4 promoter through the RRE [33] . In fact, RAR acts in concert with chicken ovalbumin upstream promoter transcription factor (COUP-TF) at the RRE elements on CaMK4 promoter. Indeed, in embryonic stem (ES) cells differentiated into neurons, endogenous CaMKIV is regulated by T3, and a single complex element in the rat CaMKIV 5′-flanking region confers this regulation. The isolated element is also stimulated by RA. COUP-TF1, which suppresses the T3 response and augments the RA response in vitro, binds to an overlapping sequence in the same site [33] . We surmised that in proliferating leukemia cells, CaMKII could mediate repression of RAR-mediated transactivation of the CaMK4 promoter. To investigate this, we performed transient transactivation assays with a CaMK4 promoter construct containing RRE, upstream of a fire-fly luciferase reporter gene [33] and found that RAR-β and COUP-TF conferred an 11-fold transactivation of the CaMK4 transgene, in the presence of RA (Fig. 2) . However, co-transfection of full-length CaMKII resulted in a significant, 2-fold repression of RA/RAR-β/COUP-TF/RA-mediated transactivation of CaMK4 promoter (Fig. 2) . We concluded that CaMKII inhibits CaMK4 gene expression by repressing its transcription.
Overexpression of CaMKIV in U937 cells inhibits CaMKII activation
CaMKIV is only slightly expressed in U937. To determine if CaMKIV expression could affect CaMKII expression or activation, we expressed the full-length CaMKIV using a Lenti-GFP virus system (CaMKIV) [37] , or a Lenti-GFP virus as a control (Mock). Treatment of U937 cells with the Ca 2+ ionophore ionomycin induces the autophosphorylation of CaMKII (p-CaMKII). This elevation in p-CaMKII levels was blocked in cells expressing CaMKIV (Fig. 3A) . These data suggest that CaMKIV suppresses CaMKII phosphorylation in U937 cells. Also ionomycininduced elevation of ERK phosphorylation was repressed in CaMKIV-U937 cells. Suppression of CaMKII activation by CaMKIV was further confirmed by in vitro kinase assays using CaMKII immunoprecipitates from Mock and CaMKIV-U937 cells stimulated with ionomycin (Fig. 3B) . Ionomycin induced activity of CaMKII was significantly inhibited in U937 cells over-expressing CaMKIV. Altogether, these data indicate that CaMKIV suppresses the autonomous activity of CaMKII in U937 leukemia cells.
Increased expression of CaMKIV in U937 cells restricts cell proliferation
CaMKII is a potent stimulator of growth factor-induced cell proliferation in several normal and cancer cells including U937 leukemia cells [23, 26] . As over-expression of CaMKIV suppresses CaMKII activity, we hypothesized that CaMKIV would inhibit CaMKII-dependent proliferation of U937 cells. We measured proliferation of CaMKIV-U937 and Mock-U937 cells in regular growth medium for three days, and found that the overexpression of CaMKIV in U937 cells does indeed result in a significant retardation of cell growth (Fig. 4A) . To understand whether the retardation of cell growth induced by CaMKIV was dependent on its kinase activity, we expressed a kinase-inactive mutant of CaMKIV [38] in U937 cells and found that this mutant does not affect proliferation (Supplementary Fig. S2A ). This observation suggests that the effect of the overexpression of CaMKIV on cell proliferation requires its kinase activity and is not due to an indirect, non-specific effect. To determine if the lack of increase in cell number is due to apoptosis in we tested Annexin V/propidium iodide (PI) reactivity. As shown in Fig. 4B , we did not observe any significant difference in apoptosis between CaMKIV-and Mock-U937, either in the presence or the absence of serum (FBS), indicating that CaMKIV-induced inhibition of proliferation was not secondary to a cell survival defect. On the contrary the growth retardation observed in CaMKIV-U937 was due to reduced cell proliferation, as shown by [ 3 H] thymidine (T) uptake assay, in Fig. 4C . A similar 2-fold inhibition of [ 3 H] T uptake was observed in Mock-U937 cells treated with either KN-93 or AntCaNtide, whereas these inhibitors had no effect on [ 3 H] T uptake by CaMKIV-U937 cells. Taken together, these data support the hypothesis that CaMKIV expression negatively regulates cell proliferation.
CaMKIV induces G 0 /G 1 cell cycle arrest in U937 leukemia cells
We analyzed the cell cycle profile of U937 cells over-expressing CaMKIV to determine at which stage of the cell cycle CaMKIV played its inhibitory role. Flow-cytometric analysis of DNA content showed a significant 3.5-fold increase in the percentage of cells arrested in the G 0 /G 1 phase in CaMKIV-U937cells. Conversely, the fraction of CaMKIV-U937 cells in S and G 2 /M phase was significantly decreased (Fig. 5A) , suggesting that over-expression of CaMKIV in myeloid leukemia cells results in G 0 /G 1 arrest, a feature that is consistent with cell quiescence. We therefore probed these cells with an antibody against the nuclear protein Ki-67, which is present in all cycling cells but uniquely absent in quiescent (G 0 ) cells [39, 40] . By combining Ki-67 reactivity with DNA content analysis (7AAD), we assessed G 0 , G 1 and S-G 2 -M populations (Fig. 5B ) and found that expression of CaMKIV increases the number of Ki-67 and 7AAD double negative cells (G 0 ) (Fig. 5Bi and Bii). This accumulation of CaMKIV-U937 cells in the G 0 /G 1 phase of the cell cycle requires its kinase activity as expression of a CaMKIV-K71M mutant did not elicit a G 0 /G 1 arrest in U937 cells (Supplementary Fig. S2 ). CaMKIVmediated cell cycle arrest was further confirmed through BrdU labeling combined with 7AAD profile analysis. Thus, a significantly lower population of CaMKIV-U937 cells entered S-phase of the cell cycle compared to Mock U937 ( Fig. 5Ci and Cii), further indicating that expression of CaMKIV in U937 cells results in the induction of G 0 /G 1 cell cycle arrest. , 15 min) . Levels of CaMKIV, p-CaMKII, total CaMKII, p-ERK and Actin were visualized by immunoblot analyses (n = 3). B) CaMKIV effect on CaMKII activation was determined by in vitro kinase assays. Endogenous CaMKII was immunoprecipitated from Mock or CaMKIV-U937 cells stimulated for 15 min with 2 μM ionomycin. The activity of immunoprecipitated CaMKII was measured by in vitro kinase assays using its specific peptide substrate, Autocamtide. Results are presented as total incorporated counts per minute (cpm). Average ± SD values from n = 4 experiments are shown. *p-value ≤ 0.05.
CaMKIV expression in U937 induces upregulation of Cdk inhibitors p27 kip1
and p16 ink4a and downregulation of cyclins A, B1 and D Progression of cells through the G 1 -S phase of the cell cycle requires hyper-phosphorylation of the retinoblastoma protein (Rb; p-Rb) by G 1 cyclin-Cdk complexes and subsequent activation of the E 2 F family of transcription factors [41] . To probe the mechanism(s) by which CaMKIV orchestrates G 0 /G1 arrest in U937 cells, we analyzed the expression levels of G 1 -CDKIs. Mock-U937 cells displayed a typical expression profile of actively proliferating tumor cells, with low levels of p27 kip1 and barely detectable p16 ink4a (Fig. 6A , densitometry showed in Supplementary Fig. S3A ). In addition, they possessed markedly elevated p-Rb levels, both in basal conditions and following FBS stimulation. In contrast, in CaMKIV-U937 we observed significant downregulation of p-Rb in CaMKIV-U937 cells and an upregulation of p27 kip1 and p16 ink4a , consistent with a G 0 /G1 arrest ( Fig. 6A and Supplementary Fig. S3A ). These data suggest that modulation of G 1 -CDKIs expression is a key mechanism by which CaMKIV may suppress U937 cell proliferation.
We further examined the modification of cyclin expression in U937 cells. CaMKIV-U937 expressed significantly lower levels of cyclin D1 under basal conditions and following stimulation with FBS, which explains the reduced proliferation and G 0 /G 1 arrest that we observed in U937 cells over-expressing CaMKIV.
We also evaluated whether over-expression of CaMKIV modulates the expression of cyclins A and B1, which regulate entry of cells into G2/M phases of the cell cycle in a CaMKII dependent manner [6, 7] . In comparison to control, CaMKIV-U937 showed lower levels of cyclin A in both basal and stimulatory (FBS) media (Fig. 6B and Supplementary Fig. S3B ), suggesting the reduced ability of these cells to progress through the S-G2 phases of the cell cycle. Interestingly, a product of degradation of Cyclin A was detectable only in CaMKIV-U937 cells, which is consistent with enhanced turnover of cyclin A, possibly due to elevated p27 kip1 42 . Furthermore, the levels of cyclin B1 after serum stimulation were also decreased in CaMKIV-U937. (Fig. 6B and Supplementary Fig. S3B ), indicating that CaMKIV could also impair G2-M phases entry ( Fig. 6B and Supplementary Fig. S3B ). Our data suggest that the expression of CaMKIV represses cell proliferation by forcing the cells into a G 0 /G 1 arrest via upregulation of CDKIs p27 kip1 and p16 ink4a .
CaMKII and CaMKIV expression in primary AML cells and correlation with the FAB/WHO phenothype
We also studied CaMKIV and CaMKII crosstalk in primary leukemic BM cells by Western blotting analysis. As shown in Fig. 7A, 4 AML patients showed increased expression of CaMKIV associated with simultaneous decreased activity of CaMKII (CaMKIV+/pCaMKII− patients: 10, 14, 9, 17), whereas 10 AML patients showed decreased expression of CaMKIV associated with simultaneous increase of CaMKII activity (CaMKIV−/pCaMKII + patients: 6, 3, 12, 13, 11, 8, 18, 19, 20, 21 ); we could not find an inverse correlation between CaMKIV expression and CaMKII activation only in the remaining 7 AML patients (n: 1, 2, 4, 5, 7, 15, 16).
In addition, we documented that all AML patients with the characteristic immature immunophenotype MO/M1 according to WHO classification showed increased expression of CaMKIV and decreased pCaMKII. By contrast, 10/13 AML patients with high differentiation immunophenotype M4 /M5 showed decreased expression of CaMKIV and increased pCaMKII (CaMKIV−/pCaMKII +). We also performed a Western blot analysis for pCaMKII and CaMKIV, normalized for CaMKII, on normal bone marrow cells as a control (Fig. 7B) . Neither pCaMKII nor CaMKIV were expressed in normal BM samples.
Inhibition of CaMKII activity elevates CaMKIV expression in primary monocytes from LMA patients
Since we observed CaMKIV and CaMKII crosstalk in leukemic BM cells, we also analyzed CAMKIV expression in primary monocytes of LMA patients following KN93 exposure. Monocytes were isolated from peripheral blood obtained from LMA-patients. Monocytes were serum-starved for 1 h and treated with 10 μM of KN93 for 3, 6 and 24 h. CaMKIV and CaMKII expression were analyzed by Western blot. As shown in Fig. 8 whereas the levels of total CaMKII did not change, autophosphorylation of CaMKII (p-CaMKII) was significantly reduced following 3 and 6 h of KN93 treatment, and completely inhibited at 24 h. Of note, low constitutive expression of CaMKIV in primary monocytes increased as a function of time following exposure to KN93 (Fig. 8) .
Discussion
The present study is the first demonstration of the reciprocal role of CaMKII and CaMKIV on cell proliferation in cancer cells. We demonstrated that CaMKII activation in leukemia blasts inhibits CaMKIV expression. A role for CaMKII in the regulation of proliferation and cell cycle has been demonstrated both in normal and tumor cells [3, 7, 22, 25] . One of the mechanisms by which CaMKII stimulates growth factor-induced cell proliferation is the activation of the ERK pathway [20, 43] . It has been reported that activation of CaMKII is essential for cell proliferation by facilitating G 1 -S, G 2 -M and metaphase to anaphase transitions [3, 6, 44, 45] . In contrast, CaMKIV can restrict aberrant proliferation and promote survival of hematopoietic cells by activating the CREB/Bcl2 pathway [12, 46] . However, a cross-talk between these two multifunctional CaMKs in the modulation of cell physiology has never been reported. In the present study we demonstrate a novel interplay between CaMKII and CaMKIV, which could have implications in the control of leukemia cell proliferation.
Under resting conditions, the human leukemic monocyte lymphoma U937 cells express high levels of CaMKII and very low, barely detectable, levels of CaMKIV. We provide evidences that CaMKII inhibits CaMKIV gene expression by repressing RAR-induced activation of the CaMK4 promoter. Pharmacological inhibition of CaMKII de-represses the CaMK4 promoter to enhance CaMKIV mRNA and protein expression in two different cell lines: U937 and K562. We also demonstrated that the pharmacological inhibition of CaMKII by KN93 in primary monocytes, increases the levels of CaMKIV as a function of time (Fig. 8) . It has been demonstrated that in several hematopoietic cell lines the expression of CaMKIIγ negatively correlates with the expression of CaMKIV. Whether this counterregulation is casual or mechanistic has been never investigated. We show that forced expression of CaMKIV in U937 cells suppresses CaMKII activity and its pro-proliferation function. Specifically, CaMKIV overexpression induces G 0 /G 1 cell cycle arrest in U937 cells, through upregulation of CDKIs p27 kip1 and p16 ink4a and downregulation of G 1 and G 2 /M cyclins. These findings suggest that, in U937 leukemia cells, CaMKII is a positive regulator of cell proliferation, whereas CaMKIV plays an opposite role, inhibiting cell cycle progression. Cell cycle arrest subsequent to pharmacological inhibition of CaMKII by KN93 has been reported in several myeloid leukemia cell lines, including U937, and in primary AML patient samples [26, 47] . Moreover, CaMKII levels become markedly reduced in leukemia cells undergoing growth arrest and/or terminal differentiation [47] . Results from our study are consistent with these previous findings. Further, they provide additional evidence that the block in cell cycle progression in U937 cells following pharmacological inhibition of CaMKII is, at least in part, due to the re-expression of CaMKIV, which promotes a cell cycle arrest in G 0 /G 1 .
CaMKIV induced the expression of p16 ink4a , which plays a pivotal role in cell cycle progression at the G 1 -S checkpoint. Rb and p16 ink4a acts in a common pathway, where hyper-phosphorylation of Rb results in the activation of E 2 F, leading to the expression of cyclin D1, cdc2 and cyclin A. Rb is a tumor suppressor [48] that is associated with the elevation of p16 ink4a in different cell models [49] [50] [51] , which is compromised in senescent fibroblasts and several cancers [51, 52] . Cross regulatory relationship between CaMKII and CaMKIV in the regulation of leukemia cell proliferation. In U937 cells CaMKII is expressed at very high levels while CaMKIV is barely detectable. CaMKII suppresses CaMKIV transcription whereas CaMKIV over-expression promotes the inhibition of CaMKII autonomous activity and cell cycle arrest. Previous studies have shown that CaMKII regulates the half-life of p27 kip1 by mediating its degradation via the Mek/Erk pathway [43] . Therefore, we hypothesize that by suppressing CaMKII activity, CaMKIV inhibits the proteasome-mediated degradation of p27 kip1 via the CAMKII-Erk pathway. Stabilized p27 kip1 will then inhibit Cdk4/cyclinD1 complexes, and therefore Rb phosphorylation and E2F activation. As a consequence, cell cycle progression is blocked. In this case, CaMKIV promotes cell cycle arrest (solid gray arrow). Further, expression of CaMKIV in U937 cells elevates p16 ink4a and represses cyclin A levels through unknown mechanisms and elicits cell cycle arrest (denoted by the dashed gray arrow). We conclude that CaMKIV and CaMKII oppose each other in the regulation of myeloid leukemia cell proliferation, with CaMKII promoting proliferation and CaMKIV promoting quiescence.
is a negative regulator of p27 kip1 , mainly through its activation of the ERK pathway and subsequent proteolytic degradation of p27 kip143 .
Thus CaMKIV may cause the upregulation of p27 kip1 in U937 leukemia cells, indirectly, through its suppression of CaMKII activity (Fig. 6) . Levels of cyclins A, B and D1 were considerably lower in CaMKIV-U937 cells and cyclin A appeared to be proteolytically cleaved. Previous reports suggest that p27 kip1 elicits the proteolytic cleavage of cyclin A within its N-terminal domain to form products that lack mitotic activity [42] . In dividing myeloid progenitor cells, this cleavage of cyclin A is important for the onset of differentiation [53] . The correlation between CaMKIV expression and the appearance of the A38/40 cyclin A fragment is therefore not surprising, as CaMKIV modulates the differentiation of a number of cell types, including neurons, osteoclasts, and dendritic cells [12, 27, 28, 46, 54] . Of note, we found a similar regulatory cross-talk between CaMKII and CaMKIV in primary AML cells. Indeed, CaMKII activation was associated with CaMKIV down-regulation and, conversely, CaMKIV overexpression with increased CaMKII activation. Moreover, pCaMKII activation mediating concurrent CaMKIV downregulation was associated with differentiated M4/M5 AML phenotype, whereas pCaMKII inhibition mediated by CaMKIV upregulation was associated with immature M0/M1 AML phenotype.
This inverse correlation between CaMKIV and CaMKII activation, although assessed in a limited number of samples, suggests a cross regulatory relationship between CaMKII and CaMKIV in the regulation of leukemia cell proliferation and/or differentiation. In these cells, CaMKII represses the expression of CaMKIV. In contrast, overexpression of CaMKIV exerts a negative regulation on CaMKII activation that results in inhibition of the MAPK pathway and cell cycle arrest (Fig. 9) .
Although larger studies are needed to identify the mechanisms of the crosstalk between CaMKII and CaMKIV in primary AML cells, and demonstrate the existence of a correlation between pCaMKII/CaMKIV ratio and FAB, our findings suggest that CaMKII and CaMKIV might have opposite roles in transformed leukemia cells and that the balance of their expression and activities can regulate not only cell proliferation, but also drive their differentiation.
The focus of our paper is the reciprocal regulation of CaMKII and CaMKIV as a general feature for cellular proliferation and survival. Indeed, the cellular process we describe in the manuscript is a widely diffuse feature, present in, but not restricted to, AML. Indeed, we analyzed two leukemia cell lines (U937 and K562) and a number of primary AMLs, and in these models we confirm the existence of such regulatory mechanism, even despite different patterns of oncogene expression. In particular, K562 cells are bcr-abl positive, while U937 are not. We also have some experimental data (paper in submission) that this regulation between CaMKII and CaMKIV occurs also in solid tumors and in particular in cancer cell lines such as KAT-4 and HT-29. Thyrosine kinase inhibitors, targeting proteins such as BCR-ABL, VEGFR, and Raf are currently used in the therapy of several tumors including leukemia [55, 56] , The interplay between CaMKII and CaMKIV could allow the identification of novel therapeutic targets in the same pathways to exploit in the treatment of myeloproliferative disorders.
